ICON PLCh

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

ICON PLCh
May 14, 2025, 13:48 | Blog
FDA's 'Project Interface' to provide outreach and engagement
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on LinkedIn:…
Apr 24, 2025, 10:39 | Blog
Tanja Obradovic: Improved PFS versus current SOC of taxane, trastuzumab and pertuzumab
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on LinkedIn:…
Apr 23, 2025, 11:43 | Blog
Critical challenges in cell therapy development - Friends of Cancer Research
Friends of Cancer Research shared a post on LinkedIn: "Speakers Announced! Friends of Cancer Research and…
Mar 13, 2025, 08:31 | Blog
Tanja Obradovic: Turmoil within the Biotech sector continues as financing remains a challenge
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on…
Feb 27, 2025, 10:03 | Blog
Tanja Obradovic: New option of immunotherapy for HNSCC is on the horizon
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on…
Oct 5, 2024, 08:24 | Insight
Tanja Obradovic: New Treatment for NSCLC Patients Targeting cMet Over-Expression
Tanja Obradovic shared a post on LinkedIn: "Novel antibody-drug conjugate (ADC) may be coming for…
Oct 4, 2024, 15:19 | Blog
Tanja Obradovic: FDA granted approval to selpercatinib for advanced or metastatic medullary thyroid cancer with a RET mutation
Tanja Obradovic shared a post on LinkedIn: "Outstanding news for patients with metastatic medulary thyroid…
Sep 25, 2024, 18:29 | Insight
Tanja Obradovic: Ligufalimab plus ivonescimab combined with chemo in the first-line CRC patients
Tanja Obradovic shared a post on LinkedIn: "Tackling large medical need in microsatellite stable (MSS)…
Aug 31, 2024, 16:56 | Blog
Tanja Obradovic: GI INNOVATION announced collaboration with Merck
Tanja Obradovic shared a post on LinkedIn: "Tackling challenges of cancer patients treatment after they progressed…
Jun 24, 2024, 15:49 | Insight
Tanja Obradovic: The landscape of targeting KRAS mutations just got busier
Tanja Obradovic shared on LinkedIn:          . "The landscape of KRAS mutations…
Jun 13, 2024, 14:28 | Blog
Tanja Obradovic: Testing is critical in order to support current treatment options for cancer patients
Tanja Obradovich shared on LinkedIn: "Testing is critical in order to support current treatment options…
May 22, 2024, 03:53 | Drugs
Tanja Obradovic: FDA just announced withdrawal of the approval for BridgeBio Pharma Truseltiq
Tanja Obradovic shared a post on LinkedIn: “FDA just announced withdrawal of the approval for BridgeBio…
May 20, 2024, 02:15 | Insight
Tanja Obradovic: Potential of TIGIT inhibitors to boost efficacy of PD(L)-1 inhibitor immunotherapy
Tanja Obradovic shared on LinkedIn: "Questions around potential of TIGIT inhibitors to boost efficacy of PD(L)-1…
All: 13 Posts: 1 - 100
Special Coverage